• Call Us +972 (0)4 - 828 8500
  • Email Carmel@univ.haifa.ac.il

Protekt Therapeutics Ltd.

Protection against memory and cognitive deterioration at advanced ages

Scientific Founder : Prof. Kobi Rosenblum 

Co-researchers: Dr. Iliana Barrera, Dr. Shunit Ben Ari

 

Company Background
Protekt Therapeutics Ltd. (formerly MemoFit) was co-founded by Carmel-University of Haifa Economic Corporation in 2014. The company aims to develop a drug for enhancing the long-term memory of those suffering from mild cognitive impairment (MCI), the prevalence of which is 15-20% of people aged 65 and older, according to the Alzheimer's Association. The company is financed by a syndicate of Takeda Pharmaceutical Company through its venture group Takeda Ventures Inc., OrbiMed Israel Partners, Johnson & Johnson Innovation – JJDC, Pontifax, and the Israel Office of the Chief Scientist, and has been operating since December 2015 in the FutuRx biotech incubator in Ness Ziona, Israel.

Inhibition of the enzyme PKR offers a unique approach for improving memory consolidation, as supported by a strong and growing body of preclinical and post-mortem human evidence. A PKR inhibitor (PKRi) small molecule provides an attractive and novel mechanism for modulating protein synthesis that can promote learning-related neuronal modifications, thus enhancing long-term memory.

Protekt Therapeutics aims to identify and develop a potent and selective oral PKRi for the treatment of cognitive disorders such as MCI, and as a novel approach to protect against memory and cognitive deterioration at advanced ages, for which there are significant unmet medical needs.

 

Learn more about the technology and research status [hyperlink to technology page]

Market Assessment
There are currently no marketed drugs for enhancing memory in MCI.

According to a GlobalData report, AD therapeutics across the major healthcare markets reached $5 billion in 2013, and is expected to reach $12.1 billion by 2023, at a compound annual growth rate (CAGR) of 9.16%. Among drug candidates entering the market are those that aim to treat the underlying cause of AD.

 

Innovation Investment & Partnership Opportunities
Protekt Therapeutics Ltd. received seed investment from the Carmel Innovations Fund and other partners, supporting the company’s research and development and steering it towards its present accomplishments.
Carmel Ltd. has a representative on Protekt Therapeutics’ board of directors and is seeking potential partners and/or investors to drive strong company growth and drug market disruption.

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Related pages

Kobi Rosenblum, Prof. - researcher page

Improving Memory and Combating Alzheimer's Disease: Drug Development to Improve Cognitive Functioning- technology page

Life Science Start-ups Secure Impressive Investments Totaling $8 Million- News and Events